News
The day at a glance · 3 min read
Mood · Risk-Off
-68
Sentiment, −100 to +100
ISRG Close
$350.16-4.51%
Healthcare Market Overview
Oil Price Target
$100
Healthcare Market Overview
SOTYKTU Market Coverage
7MM
Big Pharma & Biotech
Key driverBroad healthcare sector decline driven by rising oil prices nearing $100 per barrel and renewed inflation concerns pressuring Fed policy expectations
Daily briefHealthcare· Money365.Market AI ·

Healthcare Sells Off Broadly; UnitedHealth Divests Florida

Major pharma and medtech names declined sharply amid rising oil prices and inflation concerns, while managed care sees restructuring activity.

Healthcare Market Overview

Bearish
ISRGLLY
Healthcare stocks declined broadly as crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, renewing investor concerns about hotter inflation and bolstering the case for the Federal Reserve to raise interest rates. Major pharmaceutical and medical device companies registered losses ranging from 2% to over 4%, with Intuitive Surgical (ISRG) closing at $350.16, down 4.51% from the previous session.
US non-residential construction is approaching a reacceleration, driven by semiconductor and pharmaceutical facility buildouts, according to UBS analysis, suggesting underlying strength in pharma capital investment despite near-term market pressure.

Big Pharma & Biotech

Bearish

JNJ Close

$269.12-2.22%

Protagonist Buyback

$300M

LLY Change

-2.21%

ABBV Close

$248.78-2.99%

GILD Close

$146.64-2.88%
BMYJNJLLYABBVGILD
Bristol-Myers Squibb (BMY) saw coverage of SOTYKTU (deucravacitinib) through a comprehensive market analysis forecasting sales and market size through 2034, with potential extending to earlier-line use, injection-averse patients, and new immune-mediated indications across seven major markets including the United States, Germany, and France.
Johnson & Johnson (JNJ) closed at $269.12, reflecting a -2.22% change, while Protagonist Therapeutics announced a $300 million share repurchase program, with the authorization approved by its Board of Directors.
Eli Lilly (LLY) declined -2.21% amid the broader market selloff, though the company continues to draw investor interest for long-term growth prospects, with analysts examining the potential value of a $5,000 investment over a five-year horizon to 2031.
AbbVie (ABBV) closed at $248.78, registering a -2.99% shift from the previous trading day, marking one of the session's larger declines among major pharmaceutical names.
Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day, suffering a larger drop than the general market.

MedTech & Devices

Bearish

ABT Close

$105.52-2.59%
ABT
Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close, falling more than the broader market.

Health Insurance & Managed Care

Neutral
UNH
UnitedHealth Group (UNH) has sold an interest in some of its Optum Health operations in Florida to private equity company TPG Inc., divesting WellMed clinics as the health conglomerate works to recover from a collapse in profits last year. The transaction represents a strategic restructuring of UnitedHealth's primary care clinic portfolio amid broader efforts to stabilize financial performance.

FDA & Pipeline Development

Neutral

Flu Vaccine Failure Rate

70%
MRKMRNA
A comprehensive influenza A market analysis through 2036 highlights a 70% vaccine failure rate that is fueling the race for next-generation flu therapies, tracking Merck's (MRK) Cidara buyout and CD388's Phase 3 launch as Roche, Moderna, and GSK compete beyond the vaccine status quo. The 178-page report provides analysis of the Influenza A market across the United States and EU4 countries, examining emerging treatments that address the limitations of current vaccination approaches.
Innovation in central nervous system therapeutics continues to advance, with shifting emphasis from symptoms to biomarkers bolstering sector confidence in emerging CNS therapies and supporting the ongoing CNS development boom driven by breakthroughs in neurological pathologies.
Analysis of AI-driven healthcare innovation and cancer vaccines suggests these technologies could drive the next wave of healthcare advancement, with Moderna (MRNA) among companies positioned in this emerging therapeutic area.

People & Deals

Neutral
PFE
CD&R announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds, leveraging his 35-year career in the international biopharmaceutical industry to support the firm in identifying and evaluating new investment opportunities within healthcare and working with its portfolio companies globally. Caforio's appointment strengthens CD&R's healthcare investment capabilities amid active M&A and private equity activity in the pharmaceutical sector.
Pfizer (PFE) saw coverage examining the company's August performance, with the beaten-down pharmaceutical stock reviving after posting an estimates-beating quarter that helped restore investor confidence.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy